Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Aug:153:153-161.
doi: 10.1016/j.ejca.2021.05.020. Epub 2021 Jun 20.

Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial

Somnath Mukherjee  1 , Christopher Hurt  2 , Ganesh Radhakrishna  3 , Sarah Gwynne  4 , Andrew Bateman  5 , Simon Gollins  6 , Maria A Hawkins  7 , Joanne Canham  8 , Heike I Grabsch  9 , Stephen Falk  10 , Ricky A Sharma  7 , Ruby Ray  8 , Rajarshi Roy  11 , Catrin Cox  8 , Nick Maynard  12 , Lisette Nixon  8 , David J Sebag-Montefiore  13 , Timothy Maughan  14 , Gareth O Griffiths  15 , Tom D L Crosby  16
Affiliations
Clinical Trial

Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial

Somnath Mukherjee et al. Eur J Cancer. 2021 Aug.

Abstract

Aim: This is the first randomised study to evaluate toxicity and survival outcomes of two neoadjuvant chemoradiotherapy (CRT) regimens for patients with localised oesophageal adenocarcinoma (OAC) or gastro-oesophageal junction (GOJ) adenocarcinoma. The initial results showed comparable toxicity between regimens and pathological complete response (pCR) rate favouring CarPacRT. Herein, we report survival, progression patterns, and long-term toxicity after a median follow-up of 40.7 months.

Methods: NeoSCOPE was an open-label, UK multicentre, randomised, phase II trial. Eighty-five patients with resectable OAC or GOJ adenocarcinoma, ≥cT3 and/or ≥cN1 (TNM v7), suitable for neoadjuvant CRT, were recruited between October 2013 and February 2015. Patients were randomised to OxCapRT (oxaliplatin 85 mg/m2 on Days 1, 15, and 29; capecitabine 625 mg/m2 orally twice daily on days of radiotherapy [RT]) or CarPacRT (carboplatin AUC2; paclitaxel 50 mg/m2 on Days 1, 8, 15, 22, and 29). RT dose was 45 Gy/25 fractions/5 weeks. Both arms received induction chemotherapy (two cycles oxaliplatin 130 mg/m2 on Day 1, capecitabine 625 mg/m2 orally twice daily on Days 1-21) before CRT. Surgery was performed 6-8 weeks after CRT. The primary end-point was pCR. Secondary end-points were toxicity, progression-free survival (PFS), overall survival (OS), and patterns of progression.

Results: Eighty-five patients were recruited from 17 UK centres. The median OS was 41.7 months (95% confidence interval [CI] 19.6 to not reached) in the OxCapRT arm and was not reached in the CarPacRT arm (multivariable hazard ratio [HR] = 0.48, 95% CIs: 0.24-0.95, P = 0.035). The median PFS was 32.6 months (95% CIs: 17.1 to not reached) in the OxCapRT arm and was not reached in the CarPacRT arm (multivariable HR = 0.54, 95% CIs: 0.29-1.01, P = 0.053). In both arms, the distant progression was twice as common as locoregional progression.

Conclusions: OS and PFS favoured neoadjuvant CarPacRT over OxCapRT. Distant was more common than locoregional progression; therefore, priority should be given to optimising the systemic treatment component.

Clinical trial information: EudraCT Number: 2012-000640-10; ClinicalTrials.gov: NCT01843829.

Keywords: Neoadjuvant chemoradiotherapy; Oesophageal cancer; Randomised controlled trial; Surgery; Survival.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: RAS is an employee of and holds stock in Varian Medical Systems. All other authors have declared no conflicts of interest.

Figures

Fig. 1
Fig. 1
CONSORT flow diagram of trial participants.
Fig. 2
Fig. 2
Kaplan–Meier curves for the overall survival.
Fig. 3
Fig. 3
Kaplan–Meier curves for progression-free survival by trial arm.
See this image and copyright information in PMC

References

    1. van Hagen P., Hulshof M.C., van Lanschot J.J. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–2084. - PubMed
    1. Cunningham D., Starling N., Rao S. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46. - PubMed
    1. Mukherjee S., Hurt C.N., Gwynne S. NEOSCOPE: a randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma. Eur J Canc. 2017;74:38–46. - PMC - PubMed
    1. Mukherjee S., Hurt C.N., Gwynne S. NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma. BMC Canc. 2015;15:48. - PMC - PubMed
    1. Gwynne S., Spezi E., Maggs R. Prospective review of outlining in the UK NeoSCOPE esophageal trial. Int J Radiat Oncol Biol Phys. 2014;90

Publication types

Supplementary concepts

Associated data